TheJobsMapAbout QED Therapeutics
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
- Founded
- 2018
- Employees
- 11 to 50
- Total funding
- $65M
- Headquarters
- Palo Alto
Leadership
The top of QED Therapeutics's org chart, with how many people report into each leader.
Matt Outten
Chief Executive Officer
11 reports
Daniela Rogoff, MD, PhD.
Sr Vice President of Clinical Development
7 reports
Rick Panicucci
SVP of CMC
Morgan Paull
SVP of Strategy and Operations
Mike Monteith
Senior Vice President, Pharmaceutical Development, QED Therapeutics
Board
Neil Kumar
Chairman of the Board
Frank McCormick
Board Member
Jobs at QED Therapeutics
No open positions right now. Explore more companies on TheJobsMap.